Xenofon Baraliakos Selected Research

secukinumab

3/2024	Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.
11/2023	Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
1/2023	Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
4/2022	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
1/2022	Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.
1/2022	Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
12/2021	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
3/2021	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
1/2021	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
1/2021	Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xenofon Baraliakos Research Topics

Disease

86	Ankylosing Spondylitis 03/2024 - 01/2004
69	Axial Spondyloarthritis 05/2024 - 10/2012
36	Inflammation (Inflammations) 05/2024 - 10/2008
29	Psoriatic Arthritis 03/2024 - 01/2004
23	Rheumatoid Arthritis 02/2024 - 09/2014
21	Pain (Aches) 05/2024 - 11/2006
18	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024 - 07/2009
18	Necrosis 01/2023 - 07/2009
15	Non-Radiographic Axial Spondyloarthritis 05/2024 - 09/2012
13	Back Pain (Backache) 01/2024 - 01/2004
10	Rheumatic Diseases (Rheumatism) 01/2023 - 01/2017
9	Sacroiliitis 12/2023 - 03/2009
8	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2024 - 01/2010
8	Arthritis (Polyarthritis) 03/2024 - 03/2009
6	Uveitis 01/2023 - 03/2009
6	Ankylosis 01/2022 - 01/2004
5	Fatigue 02/2024 - 09/2019
5	Infections 01/2023 - 03/2007
4	Synovitis 02/2024 - 11/2016
4	COVID-19 01/2022 - 07/2021
3	Vasculitis (Vasculitides) 12/2023 - 09/2018
3	Connective Tissue Diseases (Connective Tissue Disease) 05/2023 - 11/2022
2	Neoplasms (Cancer) 05/2024 - 11/2022
2	Arthralgia (Joint Pain) 02/2024 - 02/2024
2	Atherosclerosis 12/2023 - 05/2023
2	Cardiovascular Diseases (Cardiovascular Disease) 12/2023 - 05/2023
2	Sclerosis 12/2023 - 06/2018
2	Osteoarthritis 08/2023 - 11/2022
2	Musculoskeletal Diseases (Musculoskeletal Disease) 08/2023 - 10/2021
2	Nasopharyngitis 01/2023 - 12/2018
2	Low Back Pain (Lumbago) 01/2023 - 01/2023
2	Intervertebral Disc Degeneration 01/2019 - 01/2004
2	Spinal Stenosis (Stenosis, Spinal) 01/2019 - 07/2010
2	Crohn Disease (Crohn's Disease) 12/2015 - 03/2015
1	Opportunistic Infections (Opportunistic Infection) 05/2024
1	Osteitis 02/2024
1	Tenosynovitis 02/2024
1	Communicable Diseases (Infectious Diseases) 12/2023
1	Disease Progression 12/2023

Drug/Important Bio-Agent (IBA)

26	secukinumabIBA 03/2024 - 11/2013
23	Antirheumatic Agents (DMARD)IBA 03/2024 - 01/2017
22	C-Reactive ProteinIBA 03/2024 - 03/2009
19	Interleukin-17 (Interleukin 17)IBA 03/2024 - 11/2013
17	Tumor Necrosis Factor InhibitorsIBA 03/2024 - 01/2010
14	Infliximab (Remicade)FDA Link 01/2023 - 01/2005
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023 - 01/2004
13	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2023 - 09/2006
12	upadacitinibIBA 05/2024 - 01/2022
12	Biomarkers (Surrogate Marker)IBA 05/2024 - 12/2011
12	Etanercept (Enbrel)FDA Link 03/2024 - 12/2011
12	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2024 - 11/2006
11	InterleukinsIBA 03/2024 - 01/2020
10	Janus Kinase InhibitorsIBA 06/2023 - 01/2021
10	Monoclonal AntibodiesIBA 01/2023 - 11/2013
9	Adalimumab (Humira)FDA Link 03/2024 - 12/2011
9	Biosimilar PharmaceuticalsIBA 03/2024 - 03/2015
9	ixekizumabIBA 11/2022 - 12/2018
8	GlucocorticoidsIBA 02/2024 - 09/2014
8	golimumab FDA Link 01/2020 - 12/2011
7	CytokinesIBA 08/2023 - 11/2013
7	AntibodiesIBA 01/2023 - 03/2007
6	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 07/2009
6	GLPG0634IBA 01/2023 - 12/2018
6	Certolizumab Pegol FDA Link 01/2022 - 01/2017
5	guselkumabIBA 12/2023 - 01/2020
5	bimekizumabIBA 10/2023 - 01/2020
5	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 01/2023 - 12/2011
5	Immunoglobulin A (IgA)IBA 01/2023 - 01/2019
4	Immunoglobulin G (IgG)IBA 10/2023 - 01/2019
4	Janus KinasesIBA 08/2023 - 01/2022
4	tofacitinibIBA 06/2023 - 01/2018
4	AutoantibodiesIBA 01/2021 - 01/2019
3	Interleukin-23 (Interleukin 23)IBA 12/2023 - 12/2021
3	Interleukin-12 (IL 12)IBA 01/2023 - 03/2015
3	Analgesics (Analgesic Drugs)IBA 01/2023 - 06/2017
3	Prednisolone (Predate)FDA LinkGeneric 10/2022 - 09/2014
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 04/2019
2	Interleukin-23 Subunit p19IBA 03/2024 - 09/2022
2	Abatacept (Orencia)FDA Link 02/2024 - 01/2020
2	Antiviral Agents (Antivirals)IBA 02/2024 - 01/2023
2	Ustekinumab (CNTO 1275)FDA Link 01/2023 - 03/2015
2	risankizumabIBA 01/2023 - 01/2020
2	VaccinesIBA 12/2022 - 10/2021
2	Dopamine Receptors (Dopamine Receptor)IBA 11/2022 - 01/2022
2	propylene diquat (PDQ(+))IBA 04/2021 - 07/2017
2	AntigensIBA 01/2021 - 05/2020
2	FluoridesIBA 06/2018 - 09/2015
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 03/2024
1	acetyl 4-aminosalicylic acidIBA 02/2024
1	Anti-Citrullinated Protein AntibodiesIBA 02/2024
1	InterferonsIBA 02/2024
1	rhenium sulfide (ReS2)IBA 12/2023

Therapy/Procedure

45	Therapeutics 05/2024 - 01/2004
9	Biological Therapy 06/2023 - 07/2013
3	Physical Therapy Modalities (Physical Therapy Technique) 01/2024 - 08/2012
3	Drug Tapering 03/2021 - 01/2020
2	Activities of Daily Living (ADL) 03/2024 - 03/2020
2	Aftercare (After-Treatment) 03/2024 - 04/2007
2	Injections 01/2020 - 12/2016
1	Precision Medicine 12/2023